Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EPS (Weighted Average and Diluted) (2021 - 2025)

HeartSciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.85 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 62.56% year-over-year to -$0.85; the TTM value through Oct 2025 reached -$6.88, up 11.91%, while the annual FY2025 figure was -$9.34, 50.16% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.85 in Q4 2025 per HSCS's latest filing, up from -$1.58 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.11 in Q2 2024 to a low of -$79.36 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$6.96, with a median of -$1.22 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 12909.84% in 2023, then soared 100.14% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.31 in 2021, then grew by 29.03% to -$0.22 in 2022, then plummeted by 7136.36% to -$15.92 in 2023, then surged by 85.74% to -$2.27 in 2024, then surged by 62.56% to -$0.85 in 2025.
  • Per Business Quant, the three most recent readings for HSCS's EPS (Weighted Average and Diluted) are -$0.85 (Q4 2025), -$1.58 (Q3 2025), and -$1.88 (Q2 2025).